William Makis has shared protocols combining Ivermectin + Fenbendazole in integrative cancer care discussions.
What’s being reported:
Dosing ranges adjusted based on case severity
Case reports describing tumor shrinkage
PSA reductions in some prostate cancer cases
Remission claims in select published reports
Why people are paying attention:
These protocols use repurposed drugs with long safety histories
Supporters argue they may target cancer through multiple pathways
Interest is growing in combining metabolic and repurposed-drug approaches
Reality check:
These protocols are experimental and not standard cancer treatment
Evidence currently relies largely on case reports, observational data, and preclinical research, not large randomized trials (PubMed)
